Computational algorithms are often used to assess pathogenicity of Variants of Uncertain 23 Significance (VUS) that are found in disease-associated genes. Most computational methods 24 include analysis of protein multiple sequence alignments (PMSA), assessing interspecies 25 variation. Careful validation of PMSA-based methods has been done for relatively few genes, 26 partially because creation of curated PMSAs is labor-intensive. We assessed how PMSA-based 27 computational tools predict the effects of the missense changes in the APC gene, in which 28 pathogenic variants cause Familial Adenomatous Polyposis. Most Pathogenic or Likely 29 Pathogenic APC variants are protein-truncating changes. However, public databases now 30 contain thousands of variants reported as missense. We created a curated APC PMSA that 31 contained >3 substitutions/site, which is large enough for statistically robust in silico analysis.
Introduction

68
Multi-gene panel testing is now routine for identifying hereditary cancer susceptibility, leading to 69 increased detection of pathogenic mutations, which can improve clinical management.
70
However, testing often identifies variants of uncertain significance (VUS), which are often 71 missense amino acid (AA) substitutions, small in frame deletions and duplications, or non-72 coding changes [1, 2] . VUS in genes that predispose to hereditary cancer and other disorders 
77
The classification of these VUS represents a major challenge in clinical genetics.
78
Computational (in silico) tools have been developed to help predict whether or not the protein 79 function will be disrupted (reviewed in [5] ). In silico tools often use Protein Multiple Sequence 80 Alignments (PMSA) to consider the evolutionary conservation and biophysical properties of the 81 wild type and variant protein to make predictions of pathogenicity. PMSA-based computational 82 methods are complicated to use properly (reviewed in [5] ). The PMSA must be of high quality 83 and sample enough species to provide reliable data [6, 7] . These in silico methods have been 84 validated for relatively few hereditary cancer genes in which pathogenic missense variants are 85 not rare (BRCA1/2, the mismatch repair [MMR] genes, TP53, a few others) [6, 8, 9, 10, 11, 12 ].
86
They have not often been validated for other genes, and for some genes predictive value was 87 not strong [13] . However, they are often cited as evidence in favor or against pathogenicity of 88 variants for genes in which validation is lacking. The American College of Genetics and to one organism, especially in areas of otherwise high homology, BLAST was used to seek 118 other homologues of the inserted sequence, and assessed the relevant nucleotide sequence for 119 plausible overlooked splice sites. 120 d) Small deletions or insertions. Short gaps that were confirmed to occur distant from an exon-121 intron boundary were allowed. The longest such gap was AA 1631-1637 in Loxodonta africana 122 (African elephant) and Trichechus manatus latirostris (Florida manatee), a highly conserved 123 region in other sequences. Because of the close taxonomic relationship between these two 124 organisms, and the fact that their sequence was assembled on the same Broad Institute 125 platform as many other species in our alignment that lack the deletion, we assessed this gap as 126 likely real.
127
We constructed two PMSAs. Our goal was to create a curated PMSA that would optimize 128 predictions for pathogenicity of variants from computational algorithms. This 10-sequence 129 PMSA contained species chosen to reflect as closely as possible the 14-species PMSA 130 previously reported for analyzing variants and validating computational algorithms in the MMR 131 genes, in which missense VUS are common and in silico interpretation is frequently used [8].
132
We identified full length APC sequences for 11 of these 14 species. The 10-species PMSA that 133 we curated using the above criteria (Table 1, Supplementary Table) . Thus, no pathogenic missense germline 202 APC variants were documented in ClinVar using these search parameters. There are n=21 203 variants (1.3% of all missense variants) with assertions of Benign or Likely Benign (B/LB). All of 204 these were classified using criteria other than in silico algorithms. Of the remaining variants in 205 ClinVar, 93.5% of the missense variants are reported as "Unknown Significance"; the rest are 206 classified as either "Other", or display conflicting assertions of pathogenicity (Table 3) .
208
Supplementary Table 3 Legend: Substitutions flanking the 12 splice sites found in Human APC were removed 222 from the list of selected missense variants. A total of 1924 variants that met the above 223 classification criteria and were not located in exon boundaries were used for analysis. Of the 224 1924 variants, 1.1% were classified as benign, none were classified as pathogenic and 98.9 % 225 were classified as uncertain or conflicting interpretation of pathogenicity. 
231
For the n=21 variants classified in ClinVar as B/LB, the prediction algorithms showed good 232 concordance with each other and with the ClinVar classifications (Table 4A ). REVEL and A-
233
GVGD showed 100% concordance with ClinVar, SIFT predicted 95.5%, PolyPhen2 81.8%, and 234 MAPP 77.8% to be Neutral. For the n=1904 variants classified as VUS, "Other", or conflicting, 235 the output differed significantly among the four non-aggregating methods (excluding REVEL).
236
The proportion of variants predicted to be "Benign" were MAPP 25.0%, PolyPhen2 41.0%, SIFT 237 68.1%, Align-GVGD 82.5% (Table 4A) 
260
We explored the hypothesis that protein structural features would be associated with the 261 likelihood that a VUS was pathogenic or benign. APC contains multiple repeats of the β-catenin 262 binding and armadillo repeats, plus domains for oligomerization, and binding to microtubules,
263
and EB1 and DLG proteins [21] . We hypothesized that missense variants 1) in the β-catenin 264 binding and armadillo repeats would be neutral, since there was domain redundancy, 2) in the 265 non-repeated domains would be more likely to be pathogenic, and 3) in unstructured regions 266 would be neutral. There was no difference in the distribution of variants classified in ClinVar as 267 neutral versus VUS relative to the beta catenin, armadillo, or other domains (Table 4b) .
268 269 
283
The same criteria (PP1_Strong, PS4_Moderate, PM1, PM2) can be applied to p.N1026S, in 284 addition to a functional defect (PS3) as reported in the literature [23, 22] . N1026 and S1028 are 285 both located in the first 15-amino acid repeat of the β-catenin binding domain and after careful 286 review are the only LP/P APC missense variants that we found in ClinVar in July 2018 that 287 satisfy the ACMG/AMP guidelines.
289
DISCUSSION 290
In silico tools have been validated with accepted standards for relatively few genes, and the field 291 would greatly benefit from refinement of standards for applying these tools. factor regarding data sets that has emerged recently is how predictors should not be evaluated 295 on variants or proteins that were used to train their prediction models. This circularity could 296 result in predictive values that are artificially inflated [24, 25] , and could occur with either likely 297 pathogenic or likely benign variants. We suggest that not enough attention has been assigned 298 to an additional important factor, the likelihood that missense substitution is a major mechanism 299 of pathogenicity for a gene. Pathogenicity is low [18], discussed below) to a higher level for these variants. The PP2 309 criterion for pathogenicity presupposes that missense is a common mechanism for mutation; 310 future studies should assess whether it is being inappropriately used when missense is a rare or 311 unknown mechanism for a given gene.
312
Our work confirms that PMSA construction remains a labor-intensive task [26] . Current 
331
One cannot assume that in silico tools that are valuable predictors for one gene will perform as 332 well for other genes. The majority of APC missense variants in ClinVar are likely to be benign,
333
given the paucity of missense pathogenic variants identified in over two decades of clinical APC 334 testing. An example of a similar gene is CDH1, in which pathogenic missense variants also are 335 rare. An expert panel studying the CDH1 gene has recommended that computational methods 336 not be used for missense CDH1 variants [28] . Thus, tools that work well for genes that are 337 commonly inactivated by missense changes [29, 30, 8, 12] can be misleading for genes that are 338 rarely inactivated by missense. For such genes, traditional in silico tools will likely overestimate 339 the probability of pathogenicity of any missense variant.
340
The ClinGen Sequence Variant Interpretation working group has estimated that the "Supporting" 341 level of evidence confers approximately 2.08/1 odds in favor of pathogenicity [18], or a 67.5% 342 probability of pathogenicity. Our current analyses of APC variants suggest that the likelihood 343 that a missense APC variant is pathogenic is far lower than 1%. Despite this, our curated APC 344 PMSA and several in silico prediction tools all predicted a significant fraction of missense 345 variants to be pathogenic. The methods that we used varied widely in their predictions for APC 346 VUS; predictions of Pathogenic or Likely Pathogenic ranged from 17.5% to 75%, all of which are 347 higher than the likely figure by at least an order of magnitude. This provides mathematical 348 support for not using in silico evidence in favor of pathogenicity (PP3 in the ACMG/AMP scheme
349
[4]) for these genes. One approach might be to create a decision tree in which a gene must 350 meet specific criteria before in silico evidence is applied. More work is needed in order to 
